Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By John T. Aquino
Jan. 6 — Agilent Technologies will pay Enzo Life Sciences $9 million to settle Enzo's litigation in federal district court alleging Agilent infringed a DNA detection patent, Enzo announced Jan. 6.
Under the settlement, the parties agreed to request dismissal of all of Enzo's claims against Agilent involving U.S. Patent No. 7,064,197 (“System, array and non-porous solid support comprising fixed or immobilized nucleic acids”) in the U.S. District Court for the District of Delaware.
A joint stipulation of dismissal was filed with the court the day of the announcement.
Agilent was one of 11 life sciences company defendants Enzo sued separately for infringement of patent composition claims that can be used for diagnostic tools for detecting analytes and as therapeutic agents.
On Oct. 13, 2015, Enzo BioChem, Enzo Life Sciences' parent company, reported global revenues for the fiscal year ended July 31 of $97 million, up 2 percent from the previous year, with life sciences' revenues down 4 percent due to a 43 percent decline in third-party royalties and fluctuations in foreign currencies.
On July 6, Enzo reached a similar $7 million settlement with Luminex Inc. and Abbott Laboratories, whom Enzo had jointly sued in the same federal district court for infringement of the ‘197 patent. That settlement also dismissed claims against Luminex that it had infringed U.S. Patent Nos. 6,992,180 and 8,097,405.
On Oct. 14, Enzo announced a $10 million settlement with Affymetrix, dismissing Enzo's claims of infringement of the ‘197 patent and Affymetrix's counterclaims.
According to Enzo's press statement, the Agilent settlement has no effect on lawsuits pending in the same court against the eight remaining defendants alleged to have infringed one or more of the three patents at issue: Hologic, Abbott, Siemens Healthcare, Illumina, Becton Dickinson, Life Technologies, Gen-Probe and Roche Molecular.
On July 7, the District of Delaware issued a claim construction decision—defining the meaning of terms in a patent claim—that Enzo announced in a press statement was favorable for Enzo's position in these litigations.
Enzo was represented by Farnan LLP, Wilmington, Del., and Desmarais LLP, New York. Agilent was represented by Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Del.
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Lee Barnes at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)